Adalimumab in the Treatment of Chronic Pouchitis
- Sponsor
- Odense University Hospital
- Study ID
- NCT01670240
- Phase
- PHASE3
- Status
- Completed
Conditions
- Pouchitis
- Ulcerative Colitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Adalimumab — DRUG
- Placebo — DRUG
Study Details
This study wants to investigate the efficiency of biological treatment for chronic pouchitis. Chronic pouchitis is inflammation in a reconstruction after removal of the colon, a pouch. It is examined in patients with ulcerative colitis. The primary objective evaluation is to evaluate the clinically effect of biological therapy (adalimumab) in patients with chronic pouchitis. Secondary objective is to evaluate the effect of biological therapy on the endoscopical and histological inflammatory activity. It is a double-blinded randomized placebo controlled study.
Key Dates
- Start date
- Aug 31, 2012
- Status verified
- Jan 2016
- Primary completion
- Sep 30, 2015
- Completion
- Jan 31, 2016
Study Design
- Enrollment
- 13 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: AdalimumabEvery second week, mg: 160-80-40-40-40-40 12 weeks in all
- Placebo Comparator: PlaceboGiven as the active comparator, every second week
Primary Outcome Measure
Clinical response on treatment with Adalimumab [ Time Frame: 12 weeks ]
Related Studies
- Immune Regulation in Ulcerative Colitis or Crohn s DiseaseRecruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Bethesda, Maryland
- Fecal Microbiome TransplantPHASE1 · Enrolling By Invitation · Judith Kelsen · Philadelphia, Pennsylvania
- Improving the Quality of Care for Adults With Inflammatory Bowel DiseaseEnrolling By Invitation · Dartmouth-Hitchcock Medical Center · Los Angeles, California
- The Influence of a Fasting Mimicking Diet on Ulcerative ColitisRecruiting · Stanford University · Palo Alto, California